Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature

Dermatology

Volumn 232, Issue 1, 2016, Pages 91-96

  Klebes, Martin ^a,b   Wutte, Nora ^a   Aberer, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Kantonsspital Muensterlingen   (Switzerland)

Author keywords

Antimalarials; Chloroquine hydroxychloroquine combination therapy; Cutaneous lupus erythematosus; Dapsone; Retrospective study; Side effects; Systemic lupus erythematosus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHLOROQUINE; DAPSONE; HEMOGLOBIN; HYDROXYCHLOROQUINE; LACTATE DEHYDROGENASE; ANTIMALARIAL AGENT;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; HEMOLYTIC ANEMIA; HUMAN; HYPERTRANSAMINASEMIA; HYPESTHESIA; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; DAPSONE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84958116575     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000441054     Document Type: Review

References (38)

1. Kuhn A, Ruland V, Bonsmann G: Hautmanifestationen des Lupus erythematodes. Z Rheumatol 2011; 70: 213-227.
2. Okon LG, Werth VP: Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol 2013; 27: 391-404.
3. Kuhn A, Ruland V, Bonsmann G: Cutaneous lupus erythematosus: update of therapeutic options. J Am Acad Dermatol 2011; 65: 195-213.
4. Winkelmann RR, Kim GK, Del Rosso JQ: Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on Oxford Centre for Evidence-Based Medicine criteria. J Clin Aesthet Dermatol 2013; 6: 27-38.
5. Wozel G, Blasum C: Dapsone in dermatology and beyond. Arch Dermatol Res 2014; 306: 103-124.
6. Working Group of the Scientific Medical Societies. Guideline of the German Dermatology Society: Kutaner Lupus Erythematodes. 2008, http://www.awmf.org/uploads/tx-szleitlinien/013-060-abgelaufen.pdf (accessed January 18, 2015).
7. Bacman D, Kuhn A, Ruzicka T: Dapsone and retinoids; in Bacman D, Kuhn A, Ruzicka T (eds): Cutaneous Lupus Erythematosus. Berlin, Springer, 2004, pp 373-390.
8. Ludgate MW, Greig DE: Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol 2008; 49: 91-93.
9. Maibach HI, Gorouhi F (eds): Evidence Based Dermatology, ed 2. Shelton, People's Medical Publishing House, 2011.
10. Lindskov R, Reymann F: Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986; 172: 214-217.
11. Coburn PR, Shuster S: Dapsone and discoid lupus erythematosus. Br J Dermatol 1982; 106: 105-106.
12. Yamada Y, Dekio S, Jidoi J, Ozasa S: Lupus erythematosus profundus-report of a case treated with dapsone. J Dermatol 1989; 16: 379-382.
13. Ruzicka T, Goerz G: Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981; 104: 53-56.
14. Holtman JH, Neustadt DH, Klein J, Callen JP: Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990; 17: 1222-1225.
15. McCormack LS, Elgart ML, Turner ML: Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984; 11: 397-401.
16. Tsutsui K, Imai T, Hatta N, Sakai H, Takata M, Takehara K: Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35: 313-315.
17. Fenton DA, Black MM: Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986; 11: 102-103.
18. Böhm I, Bruns A, Schupp G, Bauer R: ANCApositiver Lupus erythematodes profundus. Erfolgreiche Therapie mit niedrig dosiertem Dapson. Hautarzt 1998; 49: 403-407.
19. Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H: Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol 2006; 142: 399-401.
20. Pinto-Almeida T, Sanches M, Alves R, Selores M: Vesico-bullous subacute cutaneous lupus erythematosus-an uncommon entity successfully treated with dapsone and hydroxychloroquine. Dermatol Online J 2012; 18: 13.
21. Nasongkhla P, Pratchyapruit W, Tagami H: Bullous systemic lupus erythematosus induced by UVB: report a case. J Med Assoc Thai 2012; 95: 969-973.
22. Yung A, Oakley A: Bullous systemic lupus erythematosus. Australas J Dermatol 2000; 41: 234-237.
23. Hall RP, Lawley TJ, Smith HR, Katz SI: Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165-170.
24. Grover C, Khurana A, Sharma S, Singal A: Bullous systemic lupus erythematosus. Indian J Dermatol 2013; 58: 492.
25. Liu K, Shen J, Yang C, Chen YJ: Bullous systemic lupus erythematosus in a child responding to dapsone. Pediatr Dermatol 2014; 31: 104-106.
26. Tay YK, Wong SN, Tan T: Bullous systemic lupus erythematosus-A case report and review. Ann Acad Med Singapore 1995; 24: 879-882.
27. Neri R, Mosca M, Bernacchi E, Bombardieri S: A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999; 8: 240-243.
28. Seo JY, Byun H, Cho KH, Lee EB: Methimazole-induced bullous systemic lupus erythematosus: A case report. J Korean Med Sci 2012; 27: 818-821.
29. Chan Y, Mok CC, Tang WY: Erythema elevatum diutinum in systemic lupus erythematosus. Rheumatol Int 2011; 31: 259-262.
30. Lorenz M, Wozel G, Schmitt J: Hypersensitivity reactions to dapsone: A systematic review. Acta Derm Venereol 2012; 92: 194-199.
31. Zhu YI, Stiller MJ: Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45: 420-434.
32. Wozel VE: Innovative use of dapsone. Dermatol Clin 2010; 28: 599-610.
33. Pfeiffer C, Wozel G: Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2003; 48: 308-309.
34. Deps P, Guerra P, Nasser S, Simon M: Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. Lepr Rev 2012; 83: 305-307.
35. Ziemer M, Milkova L, Kunz M: Lupus erythematosus. II. Clinical picture, diagnosis and treatment. J Dtsch Dermatol Ges 2014; 12: 285-301; quiz 302.
36. Chang AY, Werth VP: Treatment of cutaneous lupus. Curr Rheumatol Rep 2011; 13: 300-307.
37. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H: Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513-518.
38. Ezra N, Jorizzo J: Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin Exp Dermatol 2012; 37: 327-334.